Exor N.V. (rated A– with a stable outlook by Standard & Poor’s) announces that it has priced €600 million notes due 5 November 2035 carrying a fixed annual coupon of 3.75%, with an issue price of 99.386%.

The purpose of the issue is to raise new funds for Exor’s general corporate purposes, including refinancing of existing debt.

The notes will be listed on the Luxembourg Stock Exchange, admitted to trading on the Euro MTF Market, and the settlement of the issue will take place on 5 November 2025.

Amsterdam, 17 September 2025

Exor N.V. (“Exor” or the “Company”) shareholders approved all resolutions proposed by the Board of Directors at the Annual General Meeting (the “AGM”) held today in Amsterdam.

The AGM adopted Exor’s 2024 annual accounts and approved a dividend distribution of €0.49 per outstanding share, for a total of approximately €100 million. The dividend will become payable on 28 May 2025, with an ex-dividend date of 26 May 2025, and will be paid to the holders of shares held on 27 May 2025 (record date).

Exor N.V. announces the results of the Tender Offer set out in the Offer Memorandum published by the Company on 26 March 2025. The Tender Offer closed at 17:40 CET on 23 April 2025.

On 17 April 2025, the reported closing price of the Ordinary Shares on Euronext Amsterdam was EUR 78.30 per Ordinary Share.

Exor nominates ING Chairman Karl Guha as a non-executive member of its Board of Directors, subject to approval at the Company’s next Annual General Meeting on 22 May 2025.

• NAV reached €38.2 billion at 31 December 2024, with NAV per share increasing by 9%
• Strong cash flow generation with dividends received from companies and asset disposals amounting to €1.5 billion in 2024. Active and disciplined capital allocation with increased exposure to Healthcare
• Ordinary dividend to be distributed of approximately €100 million, subject to AGM approval
• Launch of a new €1 billion share buyback program in the form of a Tender Offer starting 27 March 2025 at